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Abstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) as a novel therapy for type 2 diabetes 
is based on prevention of the inactivation process of bioactive peptides, the most important in 
the context of treatment of diabetes of which is glucagon-like peptide-1 (GLP-1). Most clinical 
experience with DPP-4 inhibition is based on vildagliptin (GalvusR, Novartis) and sitagliptin 
(JanuviaR, Merck). These compounds improve glycemic control both in monotherapy and in 
combination with other oral hyperglycemic agents. Both have also been shown to efﬁ  ciently 
improve glycemic control when added to ongoing metformin therapy in patients with inadequate 
glycemic control. Under that condition, they reduce HbA1c levels by 0.65%–1.1% (baseline 
HbA1c 7.2–8.7%) in studies up to 52 weeks of duration in combination versus continuous therapy 
with metformin alone. Sitagliptin has also been examined in initial combination therapy with 
metformin have; HbA1c was reduced by this combination by 2.1% (baseline HbA1c 8.8%) after 
24 weeks of treatment. Both fasting and prandial glucose are reduced by DPP-4 inhibition in 
combination with metformin in association with improvement of insulin secretion and insulin 
resistance and increase in concentrations of active GLP-1. The combination of DPP-4 inhibi-
tion and metformin has been shown to be highly tolerable with very low risk of hypoglycemia. 
Hence, DPP-4 inhibition in combination with metformin is an efﬁ  cient, safe and tolerable 
combination therapy for type 2 diabetes.
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Introduction
It is known that both the level and the duration of hyperglycemia in type 2 diabetes are 
closely related to the risk of developing diabetic complications (Stratton et al 2000). 
Therefore, achieving glycemic control is a prerequisite for prevention of cardiovascular 
and microvascular complications in type 2 diabetes. Lifestyle interventions, including 
dietary adjustments and increased physical activity, are cornerstones of the therapy. For 
most patients, however, pharmacological intervention is required and present guide-
lines suggest metformin to be a ﬁ  rst line treatment (Inzucchi 2000; Nathan et al 2006). 
Metformin is an inexpensive compound with documented glucose-lowering effect in 
both obese and non-obese subjects with type 2 diabetes (Inzucchi 2002; Hundal and 
Inzucchi 2003; Setter et al 2003; Consoli et al 2004; Donnelly et al 2006). Metformin 
reduces glycemic levels primarily by inhibiting hepatic glucose output (Bailey and 
Turner 1996; Leverve et al 2003; Stumvoll et al 1995). Metformin has also been shown 
to improve insu  lin sensitivity in liver and muscle (Ginnarelli et al 2003). Additional 
suggested mechanistic effects of metformin are inhibition of glucose absorption in the 
gut (Ikeda et al 2000) and increase in plasma levels of GLP-1 (Mannucci et al 2001). 
As has been reviewed (Bailey and Turner 1996), metformin reduces HbA1c levels in 
the range of 1%–1.5%, depending on the baseline HbA1c levels and the compound is 
well tolerated, although gastrointestinal adverse events are quite common during the 
initiation of the therapy. Hypoglycemia is rarely seen during metformin therapy, and the Vascular Health and Risk Management 2008:4(2) 384
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potential fatal adverse event of lactic acidosis is uncommon; 
nevertheless cautious should always be exercised when treat-
ing subjects with renal insufﬁ  ciency with metformin.
Add-on treatment to metformin 
often required
In spite of the beneﬁ  cial effects of metformin in improving 
glycemic control, very often, however, metformin alone 
is insufﬁ  cient for achievement of good metabolic control. 
Often, also, glycemic control deteriorates in metformin-
treated patients. This necessitates combination therapy by 
adding a secondary compound to metformin. Most often, 
sulphonylureas are added (Inzucchi 2002; Nathan et al 
2006). The rationale for this combination is that sulphonyl-
ureas stimulate insulin secretion, which is a complimentary 
mechanism to the improvement in insulin sensitivity by 
metformin. Other combinations with metformin include 
thiazolidinediones and insulin (Hundal and Inzucchi 2003; 
Setter et al 2003; Charbonnel et al 2005; Derosa et al 2006; 
Umpierrez et al 2006). However, the combinations with sul-
phonylureas and thiazolidinediones have faced problems, in 
that sulphonylureas increase the risk of hypoglycemia (Del 
Prato and Pulizzi 2006; Green and Feinglos 2007) and thia-
zolidinediones result in weight gain and potential problems of 
cardiovascular adverse events and increase in the risk of bone 
fractures in women (Kahn et al 2006; Levetran 2007; Nissen 
and Wolski 2007). Also the novel GLP-1 based therapy has 
been found to be successful in combination with metformin. 
This applies both to the strategy of activating the GLP-1 
receptors by exenatide (DeFronzo et al 2005) or liraglutide 
(Feinglos et al 2005), and by the strategy of preventing the 
inactivation of endogenous GLP-1 by inhibiting dipeptidyl 
peptidase-4 (DPP-4) (Ahrén et al 2004; Charbonnel et al 
2006; Bosi et al 2007; Brazg et al 2007; Goldstein et al 
2007). This review summarizes the experience of combining 
metformin and a DPP-4 inhibitor in the treatment.
GLP-1 as a target for treatment 
of type 2 diabetes
The rationale for the development of DPP-4 inhibition 
in the treatment of type 2 diabetes relies on augmentation 
of the incretin effect (Holst and Deacon 1998). The incre-
tin effect is the exaggerated insulin secretion that follows 
oral glucose administration when compared to intravenous 
glucose administration and it is attributed to gut hormones 
augmenting glucose-stimulated insulin secretion (Drucker 
and Nauck 2006). The two most important incretin hormones 
are glucose-dependent insulinotropic polypeptide (GIP) and 
glucagon-like peptide-1 (GLP-1) (Drucker and Nauck 2006). 
GLP-1 is produced in L-cells, which are located mainly in 
the distal portion of the ileum. GLP-1 is released during 
meal ingestion and stimulates insulin secretion in a glucose-
dependent manner (Drucker and Nauck 2006). GLP-1 also 
inhibits glucagon secretion (Dunning et al 2005), delays 
gastric emptying (Nauck et al 1997) and induces satiety 
(Gutzwiller et al 1999). In addition, animal studies have 
presented evidence that GLP-1 increases beta cell mass by 
stimulating proliferation and inhibiting apoptosis (Perfetti 
and Hui 2004), although it should be emphasized that such 
an effect has not been demonstrated in humans. Because all 
these effects would be important in the treatment of type 
2 diabetes, GLP-1 has been developed as a novel therapy 
(Ahrén and Schmitz 2004). The development of GLP-1 as a 
therapy has, however, been complicated by its rapid inacti-
vation, which is due to removal of the N-terminal dipeptide 
end through DPP-4, which inactivates GLP-1 (Mentlein 
1999). To overcome this, two strategies have been used. 
One strategy is the development of GLP-1 receptor agonists 
(GLP-1 mimetics such as exenatide and liraglutide), which 
are resistant to DPP-4 (Ahrén and Schmitz 2004). The other 
strategy is the development of inhibitors of DPP-4, which 
prevent the inactivation of GLP-1 and thereby enhance and 
prolong the action of the endogenous incretin hormone 
(Ahrén and Schmitz 2004; Mari et al 2005; Ahrén 2007a, 
2007b). DPP-4 inhibition also prevents the inactivation of the 
other incretin hormone, GIP, and therefore the concentrations 
of the active form also of this hormone are increased dur-
ing DPP-4 inhibition (Mari et al 2005). However, since the 
action of GIP to stimulate insulin secretion is almost entirely 
lost in type 2 diabetes (Vilsbøll et al 2002), this raise of GIP 
concentrations is of less importance.
DPP-4 inhibition as a target 
for treatment of type 2 diabetes
The rational of DPP-4 inhibition for the treatment of type 
2 diabetes was outlined already in 1998 (Holst and Deacon 
1998). The ﬁ  rst proof-of-concept study of DPP-4 inhibition 
showed improved meta bolic control with reduced fasting and 
prandial glucose levels and reduction of HbA1c after 4 weeks 
of treatment of the DPP-4 inhibitor, NVP-DPP728 (Ahrén 
et al 2002). Improved glycemic control by DPP-4 inhibition 
has been conﬁ  rmed in many studies with other compounds 
and today several DPP-4 inhibitors are in the progress of 
development (Ahrén 2007a, 2007b). Most experience exists 
for vil  dagliptin (LAF237, GalvusR, Novartis) and sitagliptin 
(MK-0431, JanuviaR, Merck), which are orally active Vascular Health and Risk Management 2008:4(2) 385
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compounds, which efﬁ  ciently inhibit DPP-4 activity (Ahrén 
2006; Kim et al 2005). Both compounds inhibit plasma 
DPP-4 activity for more than 16 hours after a single admin-
istration and are therefore both possible to administer once 
daily. Furthermore, they have both been shown to improve 
glycemic control when used in monotherapy as well as in 
combination therapy with metformin and thiazodilidinedione 
(Ahrén 2006; Deacon 2007; Gallwitz 2007). Sitagliptin has 
been approved for treatment of type 2 diabetes in the US and 
in Europe in combination with metformin and vildagliptin has 
been approved for treatment of type 2 diabetes in Europe. Of 
particular importance is that DPP-4 inhibitors are safe and 
tolerable and that this in combination with their efﬁ  ciency 
allow them to be used in early stages of the disease. One 
such early indication would be to use DPP-4 inhibitors in 
combination with metformin.
Rationale for combining metformin 
with DPP-4 inhibition
Type 2 diabetes develops when insulin secretion is insuf-
ﬁ  ciently raised to match insulin resistance (Kahn 2001; 
DeFronzo 2004). In addition, glucagon levels are inap-
propriately elevated, which enhances hepatic glucose 
output and increases fasting glucose (Dunning et al 2005). 
Therefore, diabetes is a disease with at least three main 
defects, which need to be corrected: impaired insulin secre-
tion, insulin resistance and hypersecretion of glucagon. The 
rationale for combining metformin with DPP-4 inhibitors is 
the complimentary mechanism of action of the two strate-
gies. Thus, metformin acts primarily by reducing hepatic 
glucose output and improving insulin sensitivity in liver 
and muscle (Stumvoll et al 1995; Bailey and Turner 1996; 
Hundal and Inzucchi 2003; Leverve et al 2003; Setter 2003) 
whereas DPP-4 inhibitors act by increasing GLP-1 levels 
and thereby stimulating insulin secretion and inhibiting 
glucagon secretion (Ahrén 2007a; Ahrén 2007b). The two 
strategies therefore have the potential to improve different 
mechanisms, which are defective in type 2 diabetes and 
therefore an additive or synergistic action when used in 
combination is anticipated. In addition, metformin has been 
shown to increase GLP-1 levels (Mannucci et al 2001), which 
would be a potential for an additional synergistic ac tion with 
DPP-4 inhibitors. The mechanism underlying the increase in 
GLP-1 levels by metformin remains to be ﬁ  nally established; 
it has been suggested to be caused by inhibition of DPP-4 
(Lindsay et al 2005; Mannucci et al 2001), although there are 
also ﬁ  ndings that metformin does not affect DPP-4 activity 
(Hinke et al 2002). Instead, more recent ﬁ  ndings suggest 
that metformin stimulates the secretion of GLP-1 from the 
gut (Migoya et al 2007). Hence, from a mechanistic point 
of view, there is a clear rationale for combining metformin 
with DPP-4 inhibitors. Another important information is that 
the pharmacokinetics of metformin and a DPP-4 inhibitor do 
not change by combining the two, as shown for sitagliptin, 
which further indicates the feasibility of the combination 
(Herman et al 2006).
Vildagliptin and sitagliptin 
as monotherapy
Both vildagliptin and sitagliptin reduce fasting and prandial 
glucose as well as HbA1c when used in monotherapy for the 
treatment of type 2 diabetes; HbA1c has been shown to be 
reduced by these compounds by 0.65%–1.1% after study 
periods of 3–12 months from baseline levels of 7.2%–8.7% 
(Ahrén et al 2004b; Ristic et al 2005; Aschner et al 2006; 
Pratley et al 2006; Raz et al 2006; Rosenstock et al 2007; 
Schweizer et al 2007; Scott et al 2007). Furthermore, these 
studies have shown that both vildagliptin and sitagliptin are 
safe and tolerable with incidences of adverse events not dif-
ferent from what is seen after placebo treatment and that there 
is a very low rate of hypoglycemia during the treatment with 
the DPP-4 inhibitors. Recent reviews have summarized these 
monotherapy studies in more detail (Ahrén 2007a, 2007b).
DPP-4 inhibition as add-on therapy 
to metformin
Several studies have reported the experience of treatment with 
a DPP-4 inhibitor in combina  tion with metformin. The ﬁ  rst 
combination study was a 52 week trial, in which vildagliptin 
at 50 mg daily or placebo was added to ongoing treatment with 
metformin (1.5–3 g daily) in patients with a mean baseline 
HbA1c of 7.8% (Ahrén et al 2004a). The patients had a mean 
diabetes duration of 5.5 years and they had been on metformin 
treatment for 29 months as a mean. The results are illustrated 
in Figure 1 and show that following the ini  tial 12 week 
study period, HbA1c was reduced by 0.7% by vildagliptin in 
combination with metformin compared to metformin alone. 
After the ﬁ  rst 12 weeks of study, patients were followed 
for another 40 weeks. During this period, HbA1c increased 
by 0.066%/month in patients given metformin alone versus 
only by 0.013%/month after vildagliptin plus metformin. 
The between-group difference in change of HbA1c after 52 
week of treatment was 1.1%, showing a clinically important 
improvement of the glycemic control by adding vildagliptin 
to metformin. Furthermore, fasting glucose was also reduced 
by vildagliptin in combination with metformin compared to Vascular Health and Risk Management 2008:4(2) 386
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metformin alone. Thus, from a mean baseline fasting glucose 
of 9.8 mmol/l across all patients, the between-group difference 
in fasting glucose after 52 weeks of treatment was 1.1 mmol/l. 
The study therefore suggests that addition of vildagliptin to 
metformin prevents the deterioration of glycemic control seen 
in these patients when given metformin alone. The study also 
shows that the combination of vildagliptin and metformin is 
safe and highly tolerable with an overall incidence of any 
adverse event being similar in the two groups.
A second study in 416 patients added vildagliptin at 50 
mg once or twice daily to on-going treatment with metformin 
for a study period of 24 weeks (Bosi et al 2007). The patients 
in this study had a mean diabetes duration of 6 years and 
had been treated with met  formin for a mean of 16 months, 
their mean daily metformin dose was 2.1 g (inclusion criteria 
1.5 g daily). They had a mean baseline HbA1c was 8.4%. 
Figure 2 shows the HbA1c levels in this study. It is seen that 
HbA1c was reduced by 0.5% in patients given vildagliptin at 
50 mg daily and 0.9% in patients given vildagliptin at 100 mg 
daily, both in combination with metformin, versus an increase 
by 0.2% in patients given placebo with on-going metformin. 
The placebo-adjusted mean reduction in HbA1c was therefore 
0.7% by vildagliptin at 50 mg and 1.1% by vildagliptin at 
100 mg daily. The data were also analysed with respect to 
how many patients who experienced improved glycemic con-
trol or had a deterioration of glycemic control. The analysis 
revealed that in the group given metformin alone, 35% of 
patients had a deterioration of glycemic control and 31% 
had no meaningful change in glycemic control. In contrast, 
of the patients given vildagliptin at 50 mg in combination 
with metformin, 38% showed a meaningful improve  ment 
in glycemic control and 29% had a marked improvement in 
glycemic control (deﬁ  ned as reduction in HbA1c by more than 
1%). Also fasting plasma glucose was reduced by vildagliptin 
in combination with metformin. Baseline fasting glucose was 
9.7 mmol/l across all groups. In the group given metformin 
alone, fasting glucose increased by 0.7 mmol/l and the pla-
cebo-adjusted reduction in fasting glucose was 0.8 mmol/l 
in subjects given vildagliptin at 50 mg daily and 1.7 mmol/l 
in subjects given vildagliptin at 100 mg in combina tion with 
metformin. Except for fasting triglycerides, lipid values were 
not signiﬁ   cantly altered in any of the groups. However, fast-
ing triglycerides increased from a mean value of 2.3 mmol/l 
by 19% in subjects given metformin alone but only by 1% 
in subjects given vildagliptin at 50 mg in combination with
 metformin and by 5% in the group given vildagliptin at 
100 mg in combination with metformin. Mean body weight 
was 94 kg as a mean across all study groups and did not change
 signiﬁ  cantly in the subjects given vildagliptin at either 50 or 
100 mg daily in combination with metformin, whereas body 
weight was reduced by 1.0 kg in subjects given metformin 
alone. Finally, total number of adverse events was not signiﬁ  -
cantly different between the groups; the only difference was 
a reduction in gastrointestinal ad  verse events in the subjects 
given vildagliptin at 50 mg in combination with metformin 
(9.6%) versus in those given metformin alone (18.2%). In 
Figure 1 Time course of HbA1c in a 12 week core study and a 40 week extension study when vildagliptin (LAF; 50 mg once daily) was given as add-on to metformin (MET). 
PBO = placebo. Reproduced from Ahrén et al 2004a after permission from the American Diabetes Association.Vascular Health and Risk Management 2008:4(2) 387
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conclusion, this large study showed that vildagliptin is well 
tolerated when given as add-on to metformin for a study 
period of 24 weeks and that vildagliptin shows a clinically 
meaningful improvement in glycemic control as veriﬁ  ed by 
dose-related reductions in HbA1c and fasting glucose.
The ﬁ  rst study on the effect of sitagliptin as add-on 
therapy to patients with inadequate glycaemic control on 
metformin monotherapy was a four week study in 28 patients 
(Brazg et al 2007). The patients had a mean duration of dia-
betes of 6.6 years, the mean baseline HbA1c was 7.7% and 
the mean fasting plasma glucose was 8.4 mmol/l. The study 
showed that fasting glucose was reduced by 1.3 mmo/l by 
sitagliptin in combination with metformin versus only by 
0.4 mmol/l by metformin alone. The study also included a 
24 hr measurement of glucose after the four week treatment
 period, and this showed a reduction of glucose by approxi-
mately 1–1.5 mmol/l throughout the entire 24 h period. Both 
fasting and prandial glycemia were reduced by this degree. 
Furthermore, the number of adverse events was not different 
when sitagliptin was given in combination with metformin 
versus when metformin was given alone. Hence, this short-
term study veriﬁ  ed the efﬁ  cient improvement in glycemic 
control by the addition of DPP-4 inhibition to on-going 
metformin therapy in asso ciation with safety and tolerability 
of the combination therapy.
In a long-term study on the effect of sitagliptin as add-on to 
metformin in subjects with inadequate glycemic control, sita-
gliptin (100 mg once daily) was added to metformin (1.5 g 
daily) for 24 weeks (Charbonnel et al 2006). The study 
comprised a total of 701 patients who had a mean diabetes 
duration of 6.2 years, a mean baseline HbA1c of 8.0% and 
a mean baseline fasting glucose of 9.5 mmol/l. Figure 3 
shows the HbA1c in this study. It is seen that addition of 
sitagliptin signiﬁ  cantly reduced the HbA1c levels after the 
24 week treatment period. The placebo-subtracted reduction 
in HbA1c by sitagliptin was 0.65%. A total of 47% of the 
patients treated with sitagliptin in combination with metfor-
min reached the target of 7% in HbA1c while the target 
was reached by only 18% of the subjects given metformin 
alone. Also fasting glucose was reduced by sitagliptin in 
combination with metformin versus metformin alone; the 
placebo-subtracted reduction by sitagliptin was 1.4 mmol/l. 
The study also showed that sitagliptin in combination with 
metformin slightly, although signiﬁ  cantly, reduced total 
cholesterol and triglycerides, whereas HDL-cholesterol 
was slightly increased. Body weight was slightly reduced 
in both groups, with no difference between the groups, and, 
similarly, the degree of adverse events did not differ between 
the groups. Hence, this 24 week trial in a large number of 
patients showed that sitagliptin when added to on-going 
therapy with metformin efﬁ  ciently reduces HbA1c and fasting 
glucose in combination of being a safe and highly tolerable 
combination therapy. Following the end of the 24 week 
trial, patients who did not receive glycemic rescue medica-
tion continued to an extension study. During this exten sion, 
387 patients continued with the combination of sitagliptin 
with metformin throughout a 54 week study period. It was 
found that the mean HbA1c remained stable at 7.1% during 
Figure 2 Time course of mean HbA1c levels during 24 week treatment with vildagliptin at 50 mg daily (∆) or 100 mg daily (S) or placebo () in patients with type 2 diabe-
tes continuing stable metformin treatment (1.5 g daily). Reproduced from Bosi et al 2007 after permission from the American Diabetes Association.Vascular Health and Risk Management 2008:4(2) 388
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this entire period and, furthermore, the combination was 
well tolerated during the period (Karasik et al 2007). Hence, 
combination of sitagliptin and metformin produced a durable 
reduction in HbA1c.
Another study with sitagliptin the addition of the 
compound (100 mg once daily) with that of glipizide (dose-
titration to a maximal doe of 20 mg daily) to the on-going 
treatment with metformin (1.5 g daily) in a 52 week study 
comprising a total of 1,172 patients (Nauck et al 2007). The 
mean baseline HbA1c levels was 7.5% and this was reduced 
by 0.67% both by sitagliptin and by glipizide. The occurrence 
of hypoglycemia was higher in the group given glipizide 
(32% of patients exhibited one episode of hypoglycemia) 
than in the group receiving sitagliptin (5%). Furthermore, 
the mean body weight in creased by 1.1 kg in the group given 
glimepiride versus a reduction by 1.5 kg in the group given 
sitagliptin. Hence, also this study showed a good improve-
ment in glycemic control by the combina  tion of a DPP-4 
inhibitor with metformin.
Recently, it was also reported that the DPP-4 inhibitor, 
saxagliptin (Bristol-Myers-Squibb), improved glycemic 
control when added to metformin (DeFronzo et al 2007). 
The study comprised a total of 743 patients with a mean 
HbA1c of 8.0% and a mean fast  ing glucose of 9.8 mmol/l 
when treated with metformin alone. Saxagliptin was added 
at 2.5, 5 or 10 mg daily and the study also included a placebo 
arm; all patients continued with metformin. It was found 
that after 24 weeks of treatment, saxagliptin had reduced 
HbA1c by 0.7 or 0.8% when adjusted for placebo in the 
three arms. Fasting glucose was reduced by 0.9–1.1 mmol/l. 
As for the other DPP-4 inhibitors, also saxagliptin was 
safe and tolerable and body weight neutral when added to 
metformin.
The studies thus presented sofar with DPP-4 inhibitors 
as add-on therapy to metformin show clinically important 
improvement in glycemic control. Mean HbA1c levels are 
reduced by approximately 0.65%–1% from a baseline of 
7.8%–8.4%. Furthermore, the combination is tolerable and 
safe with similar adverse events proﬁ  le as placebo-treated 
patients given metformin alone.
DPP-4 inhibition and metformin 
as initial combination therapy
During recent years there has been a discussion of introducing 
initial combination therapy when pharmacological treatment 
is required for type 2 diabetes, in order to reach therapeu  tic 
goal at an earlier stage and to avoid or delay subsequent 
changes in therapy for the maintenance of therapeutic goal. 
One study has examined the possibility of combining DPP-4 
inhibition with metformin as initial combination (Goldstein 
et al 2007). The study was a 24-week randomized trial com-
prising 1,092 patients with type 2 diabetes having a mean 
baseline HbA1c value of 8.7% and a mean baseline fasting 
glucose of 11 mmol/l. The pa  tients were assigned to one of
six treatment arms with sitagliptin 50 mg + metformin 
500 mg twice daily, sitagliptin 50 mg + metformin 1000 mg 
twice daily, metformin alone at 500 or 1000 twice daily, 
sitagliptin alone at 100 mg once daily or placebo. The results 
showed that in all treatment groups, except the placebo group, 
Figure 3 Time course of mean HbA1c levels during 24 week treatment with sitagliptin (100 mg once daily;  ) or placebo ({) in patients with type 2 diabetes with on-going 
treatment with metformin (1.5 g daily). Reproduced from Charbonnel et al 2006 after permission from the American Diabetes Association.Vascular Health and Risk Management 2008:4(2) 389
DPP-4 inhibition plus metformin in the treatment of type 2 diabetes
a signiﬁ  cant reduction in HbA1c after the 24 week trial period 
occurred. The placebo-controlled reduc  tion of HbA1c was in 
the range of 0.8%–2.1% in the different groups (Figure 4), 
and when compar ing monother apy versus the initial combina-
tion therapy, it was found that combina tion ther apy produced 
additive effects of improved glycemic control. Hence, the 
larg  est reduction in HbA1c (2.1%) was seen in the group 
given sitagliptin 50 mg + met  formin 1000 mg twice daily. 
Similarly, fasting glucose was additively reduced by the 
combi  nation therapy, and the placebo-adjusted reduction in 
fasting glucose in the group given sitagliptin 50 mg + met-
formin 1000 mg twice daily was 3.8 mmol/l. The percent age 
of subjects in each group who reached the treatment target 
of HbA1c 7.0% was 66% in the group given sitagliptin 
50 mg + metformin 1000 mg twice daily versus only 38% in 
the group given metformin at 1000 mg twice daily alone or
20% in the group given sitagliptin at 100 mg daily alone and 
only 9% in the placebo group. Hence, the initial combi nation 
of sitagliptin and metformin efﬁ  ciently improved glycemic 
control over a 24 week study pe  riod. The number of adverse 
events was low and the incidences of gastrointesti nal ad verse 
events were similar when sitagliptin was added to metfor-
min as when metformin was given alone. Furthermore, the 
incidence of hypoglycemia was low (0.5%–2.2% in the dif-
ferent actively treated groups) and not signiﬁ  cantly different 
from the placebo group (0.6%). Finally, in regard to body 
weight, there was a signiﬁ  cant reduction in body weight 
after 24 weeks of treatment in all actively treated groups 
Figure 4 Changes in HbA1c, fasting and 2 h prandial glucose and insulin secretion (as determined by 2 hr AUCinsulin divided by AUCglucose after a meal tolerance test) after 
24 weeks treatment of sitagliptin and/or metformin, as indicated in bottom. Results reported are adjusted for changes after treatment with placebo. Fig. is drawn after results 
reported in Goldstein et al 2007.Vascular Health and Risk Management 2008:4(2) 390
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(0.6–1.3 kg) except in the group given sitagliptin alone as 
monotherapy.
Mechanisms of improved 
antidiabetic action by combining 
DPP-4 inhibitors with metformin
DPP-4 inhibitors have been shown to increase GLP-1 levels 
both under fasting conditions and following meal ingestion 
(Ahrén et al 2004b; Mari et al 2005). Furthermore, DPP-4 
inhibition improves islet func  tion by stimulating insulin 
secretion, by improving the glu  cose sensitivity of the beta 
cells, and by inhibiting glucagon secretion from the alpha 
cells (Balas et al 2007; Dunning et al 2005). This reduces 
both fasting and prandial glucose which reduces HbA1c 
levels. In contrast to GLP-1, DPP-4 inhibi  tion does not 
seem to inhibit gastric emptying (Vella et al 2007) and it 
does not reduce body weight (Ahrén et al 2004b; Aschner 
et al 2006; Pratley et al 2006; Raz et al 2006; Ristic et al 
2005; Rosenstock et al 2007; Schweizer et al 2007; Scott 
et al 2007). Metformin, on the other hand, reduces hepatic 
glucose production and improves insulin sensitivity in 
muscle and liver cells, which improve overall insulin action 
and reduce mainly fasting glucose (Bailey and Turner 
1996; Consoli et al 2994; Donnelly et al 2006; Hundal and 
Inzucchi 2003; Leverve et al 2003; Stumvoll et al 1995). 
The efﬁ  cient improved glycemic control by combing DPP-4 
inhibitors with metformin would rely on the complementary 
mechanism of the two treatments. It has therefore been of 
interest to mechanistically examine the combination of 
DPP-4 inhibition and metformin.
GLP-1 levels
One study has examined the effect of the combination of sita-
gliptin and metformin on concentrations of active and inactive 
GLP-1 after meal ingestion following 24 weeks of treatment 
(Migoya et al 2007). It was found that both sitagliptin and 
metformin alone increased the postmeal concentration of 
active GLP-1. Furthermore, when given in combination, the 
increase in active GLP-1 was more than additive, suggesting 
a synergistic action of the two compounds.
Islet effects when DPP-4 inhibition 
is added to metformin
In the initial study on the add-on of vildagliptin to 
metformin treatment, in which vildagliptin and metformin 
in combina tion was compared with metformin alone for 52 
weeks (Ahrén et al 2004a), a standardized break  fast meal 
comprising of 465 kcal was served at baseline and after 12, 
24 and 52 weeks of treatment. The study evaluated insulin 
secretion by calculating the suprabasal 30 min area under the 
C-peptide curve divided by the 30 min increase in glucose 
after meal ingestion (Ahrén et al 2005). It was found that 
glucose tolerance was improved by the combination therapy 
versus metformin alone. Thus, the mean between-group 
difference in AUCglu cose was 256 mmol/240 min compared 
to a baseline of 545 mmol/240 min. Further  more, insulin 
secretion increased gradually during the ﬁ  rst 24 weeks by 
the combina  tion therapy and thereafter remained stable 
for the remaining period of the study (Figure 5). This 
shows that the combination of vildagliptin with metformin 
improves beta cell function. The same study also evaluated 
insulin sensitivity after meal inges  tion by calculating the 
OGIS index (oral glucose insulin sensitivity index). This 
is a vali  dated index which is based on a model of glucose 
clearance in relation to meal-derived insulin data (Mari et al 
2001). It was found that OGIS gradually increased by the 
combination therapy (Figure 5). The combined estimation 
of insulin secretion and insulin sensitivity allowed the 
estimation of the adaptation index (the product of insulin 
secretion and sensitivity); the adaptation index gives a ﬁ  gure 
of the ability of the beta-cell to adapt insu  lin secretion to 
the ambient insulin sensitivity (Ahrén and Pacini 1997). 
It was found (see also Figure 5) that the adaptation 
index increased by the combination of vildagliptin and 
metformin versus metformin alone. This change in 
adaptation index across the entire study group showed a 
negative correlation with the change in HbA1c (r = −0.39, 
p = 0.004) (see Figure 5). Hence, this analysis of potential 
mechanisms of action underlying the im  proved glycemic 
control by the combination of vildagliptin and metformin 
versus metformin alone showed a marked improvement 
in beta cell function and a slight improvement in insulin 
sensitivity which together results in improved beta cell 
adaptation ability to insulin resistance, a measure that 
correlated to the reduction in HbA1c. Furthermore, from 
this study, also baseline and prandial proinsulin levels 
have been carefully analyzed, and the results have shown a 
reduction in proinsulin levels in subjects given vildagliptin 
and metformin in combination versus metformin alone 
(Ahrén et al 2007), which further adds to the conclusion 
that vildagliptin improves beta cell func  tion when added 
to metformin in subjects with type 2 diabetes.
Another study has examined glucose tolerance and indirect 
markers of beta cell function after meal ingestion following 
24 weeks of addition of vildagliptin at 50 or 100 mg daily Vascular Health and Risk Management 2008:4(2) 391
DPP-4 inhibition plus metformin in the treatment of type 2 diabetes
to on-going metformin (1.5 g daily) (Bosi et al 2007). A 
standard breakfast consisting of 500 kcal was served after 
the 24 week treatment. Glucose tolerance was determined by 
prandial glucose levels. Insulin secretion was evaluated by 
calculating the total 2 h insulin secretion by deconvoluting 
plasma C-peptide levels and then dividing this ﬁ  gure by the 
area under the 2 h glucose curve. It was found that following 
the 24 weeks of treatment, subjects given vildagliptin (either 
50 or 100 mg daily) in combination with metformin had 
lower fasting and prandial glucose than subjects given 
metformin alone. For example, the placebo-adjusted mean 
2 hr plasma glucose following meal ingestion was reduced by
1.9 mmol/l by vildagliptin at 50 mg daily and by 2.3 mmol/l 
by vildagliptin at 100 mg from a baseline of 13.5 mmol/l. 
Furthermore, beta cell function, was increased in subjects 
given vildagliptin in combination with metformin versus 
metformin alone.
Insulin secretion and insulin sensitivity were also deter-
mined in the four week study when sitagliptin at 50 mg 
twice daily was given to on-going metformin therapy (Brazg 
et al 2007). Insu  lin secretion was evaluated by modeling C-
peptide data after a standardized breakfast meal comprising 
765 kcal (Breda and Copbelli 2001) and insulin sensitivity 
was determined with a composite index, insulin sensitivity 
index (Matsuda and DeFronzo 1999). It was found that insu-
lin secretion, as evaluated by this model, was signiﬁ  cantly 
improved after treatment with sitagliptin in combination with 
metformin versus with metformin alone (Brazg et al 2007). 
Furthermore, insulin sensitivity was numerically increased, 
although this did not reach signiﬁ  cance. Finally, the authors 
also calculated the disposition index, which is insulin secre-
tion (based on insulin levels) times insulin sensitivity, and 
it was substantially elevated by the combination therapy. 
Therefore, also this study showed a clear stimulation of 
Figure 5 Insulin secretion (evaluated as the 30 min suprabasal AUCC-peptide following meal ingestion divided by the 30 min increase in glucose), insulin sensitivity (evaluated 
by the OGIS estimation) and adaptation index (insulin secretion times insulin sensitivity) at baseline and after 12, 24 and 52 weeks of treatment with vildagliptin at 50 mg 
daily in combination with metformin (n = 31) versus treatment with metformin alone (n = 26). Low right panel shows the change in HbA1c after the 52 week treatment 
period as a function of change in adaptation index in the same study. Reproduced from Ahrén et al 2005 after permission from the American Diabetes Association.Vascular Health and Risk Management 2008:4(2) 392
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insulin secretion by the combination of met  formin with a 
DPP-4 inhibitor.
Beta cell function and insulin sensitivity were as well 
estimated in the 24 week study with sitagliptin at 100 mg 
once daily as add-on to metformin (Charbonnel et al 2006). 
It was found that after 24 weeks of treatment, along with 
a reduction in HbA1c and fasting glucose, the combina  tion 
of sitagliptin and metformin increased fasting insulin and 
glucose as well as the homeostasis model assessment of 
β-cell function (HOMA-β, Matthews et al 1985) and the 
insulin sensitivity marker, quantitative insulin sensitivity 
check (QUICKI, Katz et al 2000). Furthermore, the 
combina  tion of sitagliptin and metformin also reduced the 
proinsulin to insulin ratio under fasting conditions, which 
is a sign of improved beta cell function. In contrast, in this 
study, fasting proinsulin levels per se were not altered and 
the homeostasis model assessment of insulin resistance 
(HOMA-IR), which is based on the fasting levels of 
glucose and insulin (Matthews et al 1985) was not altered. 
Furthermore, in this study, the subjects also received a 
standardized meal after 24 weeks treatment. It was found 
that sitagliptin in combination with metformin signiﬁ  cantly 
reduced the post-meal glycemia in association with 
enhancement of postmeal insulin and C-peptide levels as 
well as the determination of insulin secretion by calculating 
the postmeal insulin to glucose ratio, all in comparison with 
treatment with metformin alone.
Islet function when DPP-4 inhibition 
and metformin are used in initial 
combination therapy
In the study in which sitagliptin and metformin are given 
as initial combination ther  apy (Goldstein et al 2007), a 
standardized meal tolerance test was given after 24 weeks of 
treatment with analyses of glucose, insulin and C-peptide. It 
was found that along with the reduction in fasting glucose, 
the prandial glycemia was improved both by sitagliptin and 
metformin in monotherapy but an additive effect in reducing 
prandial glycemia was observed. Thus, the placebo-adjusted 
reduction in mean 2 h postmeal glucose was 6.5 mmol/l from 
the base  line 2 hr glucose of 15.9 mmol/l in the subjects given 
sitagliptin 50 mg + metformin 1000 mg twice daily. Also insulin 
secretion, as determined by the AUCinsulin divided by AUCglucose 
during the 2 hr postmeal period, was signiﬁ  cantly increased 
by the combina  tion therapy in an additive manner versus 
monotherapy. Thus, the placebo-adjusted in  crease in mean 
insulin secretion was 0.07 µU hr insulin/ml/mg h glucose/dl 
versus 0.16 at baseline, ie, an increase by 43%. The study also 
showed a signiﬁ  cant reduction in fasting proinsulin and in 
fasting proinsulin to insulin ratios after 24 weeks treatment with 
the combination of sitagliptin and metformin, again reinforcing 
an improved beta-cell function by this combination therapy. 
Furthermore, when calculating the insulin resistance index, 
HOMA-IR, a marked improvement in insulin sensitivity was 
seen by the combination; the placebo-adjusted value of HOMA-
IR was reduced by 2.7 from a baseline of 6.2, ie, by 41%.
To summarize, the mechanistic studies of combina-
tion treatment with DPP-4 inhibition and metformin show 
increased GLP-1 levels and increased insulin secretion and 
insulin sensitivity. Nevertheless, more studies are required to 
fully understand the beneﬁ  ts of this combination, including 
effects on glucagon secretion.
Conclusions
DPP-4 inhibition has been shown to be antidiabetic 
when used both in monotherapy (Ahrén et al 2004b; 
Aschner et al 2006; Pratley et al 2006; Raz et al 2006; 
Ristic et al 2005; Rosenstock et al 2007; Schweizer 
et al 2007; Scott et al 2007) and in combination with 
metformin (Ahrén et al 2004a; Bosi et al 2007; Brazg 
et al 2007; Charbonnel et al 2006; Goldstein et al 2007), 
thiazolidinediones (Garber et al 2007; Rosenstock et al 
2006; Rosenstock et al 2007) and insulin (Fonseca et al 
2007). This novel strategy to treat type 2 diabetes is 
expected to be of increasing value in the future treatment 
of type 2 diabetes. The overall experience is that this novel 
strategy is efﬁ  cient, highly tolerable and safe with a minimal 
risk for hypoglycemic events. A promising place in therapy 
for DPP-4 inhibition is in combination with metformin. This 
has been demonstrated in large studies with vildagliptin 
and sitagliptin, since these studies have shown that HbA1c
 is reduced by 0.65%–1.1% from baseline levels of 
7.8%–8.4% in studies up to 52 weeks. This improvement in 
glycemic control is similar as in studies with sulphonylureas, 
thizolidinediones or exenatide when added to metformin 
treatment. Furthermore, DPP-4 inhibition in combina  tion 
with metformin is safe and tolerable. Hence, a major 
indication for treatment with DPP-4 inhibition as add-on 
to metformin in subjects inadequately controlled with 
metformin and as ﬁ  rst-line treatment in initial combination 
therapy with metformin. For future studies, the durability 
of effects of the combination of DPP-4 inhibition with 
metformin needs to be explored as well as more detailed 
mechanistic studies need to be undertaken, with particular 
to studies on glucagon secretion, prandial lipid levels and 
insulin sensitivity.Vascular Health and Risk Management 2008:4(2) 393
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